These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3698053)

  • 21. [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
    Hoshi S; Ohyama C; Namiki S; Hagisawa S; Satoh M; Saito S; Ono K; Shirasaka T; Arai Y
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1773-8. PubMed ID: 12402428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic agents in prostate cancer: an enigma.
    Yagoda A
    Semin Urol; 1983 Nov; 1(4):311-21. PubMed ID: 6399617
    [No Abstract]   [Full Text] [Related]  

  • 23. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prostatic cancer: indications for hormone therapy].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1979 Mar; 121(9):300-2. PubMed ID: 85258
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome.
    Moertel CG; Rubin J; O'Connell MJ
    Cancer Treat Rep; 1986 Dec; 70(12):1459-60. PubMed ID: 3791259
    [No Abstract]   [Full Text] [Related]  

  • 26. [Contribution on the clinical aspects of prostatic carcinoma].
    Sladczyk E
    Z Arztl Fortbild (Jena); 1967 Jul; 61(13):657-60. PubMed ID: 5598256
    [No Abstract]   [Full Text] [Related]  

  • 27. [Enzymological study of prostatic cancer. II. Serum lactic dehydrogenase, alkaline phosphatase, leucine aminopeptidase, total acid phosphatase, prostatic acid phosphatase activity and lactic dehydrogenase isoenzymes in prostatic cancer, with special reference to relation with stage and histological malignancy].
    Ishibe T; Nihira H; Mori K
    Hinyokika Kiyo; 1969 Apr; 15(4):254-65. PubMed ID: 5817349
    [No Abstract]   [Full Text] [Related]  

  • 28. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of cisplatin in advanced gastric cancer.
    Vogl SE; Camacho FJ; Engstrom PF; Bennett JM
    Cancer Treat Rep; 1984 Dec; 68(12):1497-8. PubMed ID: 6542449
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Late results of treatment of prostatic cancer].
    Hanschke HJ; König K; Caspar W
    Dtsch Med Wochenschr; 1968 Nov; 93(47):2271-4. PubMed ID: 5686345
    [No Abstract]   [Full Text] [Related]  

  • 32. [Phase II trial of pepleomycin in metastatic cancer of the prostate].
    Garcia-Giralt E; Guinet F; Pouillart P; Kerbrat P; Gedouin D; Allain YM; Fumoleau P
    Bull Cancer; 1986; 73(1):91-2. PubMed ID: 2430653
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of advanced metastasizing carcinoma of the prostate with estracyt (author's transl)].
    Rambausek M; Lutherer S; Terhorst B
    Urologe A; 1981 Jul; 20(4):223-7. PubMed ID: 7196632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cisplatin in patients with gastric cancer: a Cancer and Leukemia Group B phase II study.
    Perry MC; Green MR; Mick R; Schein P
    Cancer Treat Rep; 1986 Mar; 70(3):415-6. PubMed ID: 3955555
    [No Abstract]   [Full Text] [Related]  

  • 36. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of cis-diamminedichloroplatinum in patients with non-small cell lung cancer.
    Fujita J; Saijo N; Eguchi K; Shimizu E; Shinkai T; Tominaga K; Sasaki Y; Futami H; Sakurai M; Hoshi A
    Jpn J Cancer Res; 1985 May; 76(5):420-3. PubMed ID: 3924714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial.
    Williams SD; Birch R; Einhorn LH
    Cancer Treat Rep; 1986 Mar; 70(3):405-7. PubMed ID: 3955552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The clinical and prognostic value of inversion of the PSA/PAP ratio in prostatic cancer].
    Morote Robles J; Lorente JA; Reig C; López Pacios MA; de Torres JA; Soler Roselló A
    Actas Urol Esp; 1994 May; 18(5):559-61. PubMed ID: 7521563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.